The prospects for using bemiparin in prophylaxis and treatment of thromboses in oncology
https://doi.org/10.21518/2079-701X-2018-10-103-106
Abstract
Oncological patients have a high risk of thrombotic complications, which worsen the outcomes of antitumor treatment and is one of the leading causes of death. Low molecular weight heparins are the main drugs for the prevention and treatment of thrombotic complications in cancer patients. Zibor (bemiparin) is a second-generation low-molecular-weight heparin (LMWH) that has the lowest molecular weight (3600 Dalton), a half-life increased to 5.3 hours and the highest anti-Factor Xa activity ratio (8:1). In clinical trials, bemiparin has demonstrated high efficacy and safety for prophylaxis and treatment of thromboembolic complications.
About the Authors
O. V. Somonova
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD
Moscow
A. L. Elizarova
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in Biology
Moscow
Yu. A. Nesterova
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
N. N. Borisenko
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
U. A. Kornyushenko
N.N.Blokhin National Medical Research Cancer Centre of Oncology, Federal State Budgetary Institution of the Ministry of Health of Russia
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. Journal of thrombosis and Haemostasis, 2011, 9(Suppl 1): 316-324.
2. Barsam SJ, Patel R, Arya. Anticoagulation for prevention and treatment of cancer-related venous thromboembolism. British J of Haematology, 2013, 161(Iss. 6): 764-777.
3. Robin P, Carrier M. Revisiting occult cancer screening in patients with unprovoked venous thromboembolism. Thrombosis Research, 2018, 164(Suppl.1): S7-S11.
4. Magnus N, D’Asti E, Meehan B et al. Oncogenes and the coagulation system – forses that modulate dormant and aggressive states in cancer. Thrombosis Research, 2014, 133(Suppl. 2): S1-S9.
5. Falanga A, Marchetti M. Hemostatic biomarkers in cancer progression. Thrombosis Research, 2018, 164(Suppl.1): S54-S61.
6. Cedervall J, Hamidi A, Olsson A-K. Platelets, NETs and cancer. Thrombosis Research, 2018, 164(Suppl.1): S48-S52.
7. Ten CH, Falanga A. Overview of the postulated mechanisms linking cancer and thrombosis. Pathophysiol Haemost Thromb, 2007, 36: 122-130.
8. Agnelii G, Verso M. Thromboprophylaxis during chemotherapy in patients with advanced cancer. Thrombosis Research, 2010, 125(Suppl.2): S17-S20.
9. Weitz JI. Potential of new anticoagulsnts in patients with cancer. Thrombosis Research, 2010, 125(Suppl 2): S30-S35.
10. Levine MN, Lee AY, Kakkar AK. Thrombosis and cancer. American Society of Clinical Oncology, 41 Annual Meeting, 2005: 748-577.
11. Lee AY. The roles of anticoagulants in patients with cancer. Thromb Res, 2010, 125(Suppl. 2): S8-S11.
12. Cohen AT, Nandini B, Wills JO et al. VTE prophylaxis for the medical patients: where do we stand? A focus on cancer patients. Thromb. Res, 2010, 125(Suppl 2): S21-S29.
13. Lyman GH, Bohlke K, Khorana AA et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical Practice Guideline Update 2014. J Clin Oncol, 2015, 33: 654–656.
14. Kuderer NM, Lyman GH. Guidelines for treatment and prevention of venous thromboembolism among patients with cancer. Thromb Res, 2014, 133(Suppl. 2): S122-S127.
15. Kearon C, Akl EA, Ornelas J et al. Antithrombotic therapy for VTE disease. Chest, 2016, 149(2): 315-352.
16. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest, 2001, 119(Suppl. 1): 64S-94S.
17. Hirsh J, Anand SS, Halperin JL, Fuster V. Guide to Anticoagulant therapy: Heparin. A Statement for healthcare Professionals from the American Heart Association. Curculation, 2001: 2994-3018.
18. Mismetti P, Laporte S, Darmon JY et al. Metaanalysis of low-molecular-weight heparin in the prevention pf venous thromboembolism in general surgery. Br J Surg, 2001, 88: 913-930.
19. Martinez-Gonzalez J, Vila L, Rodriguez C. Bemiparin: second-generation, low-molecularweight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev Cardiovasc. Ther, 2008 Jul, 6(6): 793-802.
20. Morita S, Gebska MA, Kakkar AK, Scully MF. High affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. Blood, 2002, 99: 2221-7.
21. Balibrea JL, Altimiras J, Larruzea I et al. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. Int J Surg, 2007 Apr, 5(2): 114-119.
22. Velichko EV, Trudny Patient, 2017, 15 (10-11): 11-14.
23. Kakkar W, Howes J, Sharma V, Kadziola Z. A comparative, double-blind, randomizied trial of a new-second generation LMWH (Bemiparin) and UFH in the prevention of post-operative venous thromboembolism in patients undergoing hip arthroplasty. Thromb Haemost, 2000, 83: 523-529.
24. Navarro-Quilis A, Castellet E, Rocha E,PazJimenez J, Planes A. Efficasy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty. A randomized doubleblind clinical trial. Thromb Haemost, 2003, 1: 425-432.
25. Rodriguez-Manas L, Gomez-Huelgas R, VeigaFernandez F, Ruiz GM, Gonzalez JM. Thromboprophylaxis with the low -molecular – weight heparin bemiparin sodium in elderly medical patients in usual clinical practice: the ANCIANOS study. Clin Drug Investig, 2010, 30(5): 337-45.
26. Monreal BM, Vignoli A, Lecumberri VR et al. Bemiparin in oncology. Drugs, 2010, Dec 14, 70(Suppl 2): 35-42.
27. ABEL trial: A phase II randomized trial adding bemiparin to chemo-radiotherapy in limitedstage small cell lung cancer (SCLC) – Final results, 2912 ASCO Annual Meeting. Abstr.7095. Cit. In J Clin Oncol, 2012: 30.
Review
For citations:
Somonova OV, Elizarova AL, Nesterova YA, Borisenko NN, Kornyushenko UA. The prospects for using bemiparin in prophylaxis and treatment of thromboses in oncology. Meditsinskiy sovet = Medical Council. 2018;(10):103-106. (In Russ.) https://doi.org/10.21518/2079-701X-2018-10-103-106
Views:
625
Email this article 